List your tool

Head to head · 2026

Bioptimus vs Tempus AI

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

Bioptimus

Foundation models for biology spanning molecular, cellular and tissue scales

4.2Not listed

Visit Bioptimus (opens Bioptimus in a new tab)

Tempus AI

Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue

4.3Not listed

Visit Tempus AI (opens Tempus AI in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: Bioptimus does not list a price

  • Free plan

    Tie

    Neither has one

  • Higher rating

    Tempus AI

    4.2 against 4.3

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onBioptimusTempus AI
Our rating4.24.3Better
Starts atNot listedNot listed
Free planNoNo
CategoryHealthcare AIHealthcare AI
PlansSee pricingSee pricing
Key features
  • Foundation models trained across molecular, cellular and tissue scales
  • Digital pathology models for research and trial workflows
  • Transfer learning that reuses existing imaging and omics archives
  • Benchmarked against independent public evaluations
  • Research, clinical trial and diagnostics use cases
  • Machine learning applied to genomic and clinical data for precision treatment matching
  • One of the largest connected libraries of clinical and molecular data
  • Publicly traded on Nasdaq under the ticker TEM
  • Q1 2026 revenue of $348.1M, up 36.1% year over year
  • 2026 revenue guidance raised to $1.59-$1.60 billion
Pros
  • Cross-scale model design rather than one narrow task classifier
  • Extracts additional value from data a lab already holds
  • Published benchmark results give an external reference point
  • Publicly reported financials give unusual transparency into scale and growth
  • Massive, growing data library strengthens precision-matching over time
  • Strong, consistent revenue growth across both diagnostics and data segments
Cons
  • Requires in-house validation on local cohorts before clinical reliance
  • Enterprise-only engagement with no self-serve access
  • Pricing runs through insurance billing and enterprise agreements, not published rates
  • Built specifically for precision medicine and oncology, a narrower clinical scope
  • Best suited to institutions already positioned to act on genomic testing results
CompanyBioptimus, founded 2024Tempus AI, founded 2015

Prices come from each vendor's pricing page, last checked 20260812. Check the vendor before you buy.

FAQ

Questions people ask

Is Bioptimus better than Tempus AI?

In our reviews Bioptimus scores 4.2 and Tempus AI scores 4.3. The better pick depends on the job. Bioptimus: Foundation models for biology spanning molecular, cellular and tissue scales. Tempus AI: Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue.

Which is cheaper, Bioptimus or Tempus AI?

Bioptimus: see pricing. Tempus AI: see pricing.

Do Bioptimus and Tempus AI have free plans?

Neither lists a free plan.

More comparisons